Tiziana Life Sciences (TLSA) announced a product development services agreement with Renaissance Lakewood. This collaboration aims to optimize the current formulation and develop a comprehensive plan for the scale-up of foralumab in a nasal device. Intranasal foralumab is currently under development for treating neurodegenerative and inflammatory diseases or conditions. Under this agreement, Renaissance will use its extensive expertise in pharmaceutical-nasal product development and manufacturing to support the production of intranasal foralumab, ensuring compliance with the highest quality and regulatory requirements. This collaboration is a critical step in Tiziana’s strategy to expedite clinical development and potential commercialization of intranasal foralumab.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences Expands Access to Multiple Sclerosis Treatment
- Tiziana Life Sciences doses additional four patients in multiple sclerosis trial
- Tiziana Life Sciences Highlights Foralumab’s Potential in Alzheimer’s Treatment
- Tiziana announces TV interview with AD patient dosed with foralumab
- Tiziana Life Sciences Faces Nasdaq Compliance Challenge
Questions or Comments about the article? Write to editor@tipranks.com